A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

Robert J. Amato, J. Jac, S. Giessinger, +2

Cancer

A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC)

R. J. Amato, Patricia Harris, Martin L. Dalton, +7

Journal of Clinical Oncology

Therapeutic Drug MonitoringIntra-patient Dose-escalated SorafenibUrologyPhase Ii TrialGenitourinary Cancer +13

The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT)

BS Teh, C. Bloch, M Galli-Guevara, +11

Biomedical Imaging and Intervention Journal

Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α)

Robert J. Amato, William Shingler, Madusha Goonewardena, +7

Journal of Immunotherapy

ImmunologyImmunoeditingImmunodominancePathologyImmunotherapeutics +19

Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial

Robert J. Amato, William Shingler, Stuart Naylor, +5

Clinical Cancer Research

Vaccination of Prostate Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax)

Robert J. Amato, Noel Drury, Stuart Naylor, +5

Journal of Immunotherapy

Prostate Cancer PatientsImmunologyImmunoeditingImmunotherapeuticsImmunotherapy +14

Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer

Robert J. Amato, J. Jac, Somya Saxena

Clinical Genitourinary Cancer

UrologyGenitourinary CancerMedicineProstatic DiseaseOncology +3

A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)

J. Jac, S. Giessinger, Muhammad Khan, +3

Journal of Clinical Oncology

PathologyTumor BiologyOncologyGenitourinary CancerCancer Cell Biology +14

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma

Amita Patnaik, Glen J. Weiss, K. Papadopoulos, +9

British Journal of Cancer

Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.

Tony Mok, E. Tan, K. Park, +8

Journal of Clinical Oncology

ImmunologyPathologyPhase Ii StudyImmunotherapyFibroblast Growth Factor +16